Platelet surface receptors involved in hemostasis

Platelet surface receptors are a diverse group of membrane-bound proteins that mediate the critical steps of hemostasis, including platelet adhesion, activation, and aggregation (NCBI: Platelet Receptors as Antithrombotic Targets, 2017). These receptors are categorized into several families, such as integrins (e.g., Integrin alpha-IIb beta-3), G protein-coupled receptors (e.g., P2Y12 and PAR1), and leucine-rich repeat glycoproteins (e.g., Glycoprotein Ib-IX-V complex) (StatPearls: Platelet Physiology, 2023). Upon vascular injury, these receptors interact with ligands like collagen, von Willebrand factor, thrombin, and ADP to initiate intracellular signaling that leads to the formation of a stable platelet plug. Because of their central role in thrombus formation, many of these receptors are primary targets for antiplatelet therapy in the treatment and prevention of cardiovascular diseases like myocardial infarction and stroke (Journal of Thrombosis and Haemostasis, 2021). For instance, P2Y12 inhibitors and GPIIb/IIIa antagonists are widely used to prevent ischemic events in patients with coronary artery disease. However, therapeutic intervention must carefully balance the prevention of pathological thrombosis with the maintenance of physiological hemostasis to avoid excessive bleeding complications. Emerging therapies also target receptors like GPVI and GPIb to potentially decouple antithrombotic effects from bleeding risks.

Other names

Platelet receptorsHemostatic receptorsPlatelet glycoprotein receptorsPlatelet activation receptorsPlatelet membrane glycoproteins

The primary mechanisms of action include the antagonism of the P2Y12 ADP receptor, inhibition of the Glycoprotein IIb/IIIa (Integrin alpha-IIb beta-3) receptor to prevent fibrinogen binding, and blockade of the Protease-activated receptor 1 (PAR1) to inhibit thrombin-induced activation (StatPearls: Platelet Physiology, 2023; NCBI: Platelet Receptors as Antithrombotic Targets, 2017).